Venture capitalists are pouring hundreds of millions of dollars into healthcare startups pitching lower cost alternatives to traditional services and one of their primary targets is diagnostics.
As investors look to back services that can pitch lower cost alternatives to customers, companies like EverlyWell, the Disrupt Battlefield alumnus which just raised $50 million in new financing start to look more appealing.
Since its launch on our San Francisco stage in 2016, EverlyWell has expanded from eight test kits that use blood, saliva, or urine to diagnose a variety of ailments (from food sensitivities to high cholesterol to fatigue) to now pitching a total of 35 in-home testing offerings to consumers.
The same pressures on American consumers continue to drive EverlyWell’s growth. More employees are opting